MRSA Screening Programme National Targeted Rollout. MRSA Screening

Size: px
Start display at page:

Download "MRSA Screening Programme National Targeted Rollout. MRSA Screening"

Transcription

1 National Targeted Rollout. MRSA Screening A resource pack to support the training of healthcare staff 5th February 2010

2 Xxxx Learning Outcomes Xxxx On completion of this course you should be able to: Give a definition of MRSA. Describe the rationale for MRSA screening. Identify the patient areas that are subject to MRSA screening. Describe how to take a nasal swab. Explain how a nasal swab is processed in the microbiology department. Describe action to be taken following a positive MRSA result. 2

3 Xxxx Contents Xxxx Section 1. MRSA and MRSA Screening. Section 2. Who should be screened for MRSA? Section 3. How to take a nasal swab? Section 4. Processing of a nasal swab in the Microbiology department. Section 5. Action to be taken on receipt of a positive MRSA result. Resources Appendix 1. Hand Hygiene. Appendix 2. Questions and Answers. 3

4 Section 1. MRSA and MRSA Screening This section will describe what MRSA is, the terms colonisation and infection and what a MRSA screen involves.

5 Xxxx What is MRSA? Xxxx MRSA stands for Meticillin-resistant Staphylococcus aureus. MRSA is a bacterium (micro-organism). MRSA is a type of Staphylococcus bacteria that can live on the skin of healthy people, but in some cases can also cause an infection. Staphylococcus aureus is an micro-organism that one third of the population carries on their skin and/or in their nose. MRSA is resistant to an antibiotic called meticillin thus the name Meticillin-resistant Staphylococcus aureus. It is resistant to antibiotics such as flucloxacillin, the antibiotic often used to treat Staphylococcus aureus infections. It may also be resistant to a variety of other antibiotics. Some people carry MRSA on their skin and in their nostrils without knowing it and without it causing any harm. This is called colonisation. If MRSA causes an infection these are the same types of infection caused by Staphylococcus aureus. MRSA infection can be treated with antibiotics although the choice may be more limited and treatment time prolonged. 5

6 What is the difference between colonisation and infection? Colonisation Many people are unaware that they carry MRSA on their skin or in their nose as it does not harm them and they have no symptoms. A patient from whom MRSA is identified but has no signs or symptoms of an infection is said to be colonised with MRSA. Infection Infection occurs when a micro-organism such as MRSA gains entry to the body. This could be via an open wound or invasive devices and multiplies (grows) in the tissue. Infections vary in severity. Patients at particular risk from infection are surgical patients, intensive care patients, immunocompromised patients and patients with open wounds or invasive devices. Symptoms of infection depend on the nature and severity of the infection. Generally there is an increase in the person s temperature. If localised infection is suspected (this is where infection is limited to a small area on the body) there may be signs of redness, swelling, pain with or without a purulent (pus) discharge. 6

7 How is MRSA spread? MRSA is spread by direct or indirect contact. Direct contact Direct contact occurs during skin to skin contact. For example micro-organisms can be transferred via the hands of healthcare staff who have contact with a patient who is colonised or infected with MRSA. Indirect contact Indirect contact takes place when a person has contact with a contaminated object such as equipment which is in the environment of a colonised or infected person or equipment which has been contaminated with MRSA. 7

8 What is MRSA screening? MRSA screening is when a patient is tested for the presence of MRSA on or before admission. MRSA screening is a microbiological test where a swab sample is taken from a carriage site (e.g. nostrils). This is the process which identifies which patients are colonised with MRSA. The nose is the most common carriage site for MRSA. 8

9 Section 2. Who should be screened for MRSA? This section will describe the work by NHSScotland to examine the clinical and cost effectiveness of screening and the MRSA screening programme.

10 Health Technical Assessment 9: The clinical and cost effectiveness of screening for Meticillin-resistant Staphylococcus aureus (MRSA) (Ritchie et al, 2007) The above report was commissioned to consider different MRSA screening strategies and appropriate management of patients admitted to acute hospitals. The report was necessary as recent UK guidance on MRSA screening was contradictory in its recommendations. The report recommended that a primary study to be set up in acute inpatient settings to assess whether screening is effective in preventing MRSA infection. This study was called the MRSA Screening Pathfinder Programme. 10

11 MRSA Screening Pathfinder Programme Three NHS Boards agreed to take part in the study to assess whether MRSA screening is effective in preventing MRSA infection. The project allowed the collection of data to inform (1) the impact of MRSA screening, (2) test the estimates of economic model assumption and (3) estimate the feasibility for roll out of MRSA screening in NHSScotland. 11

12 NHS Scotland MRSA screening Pathfinder Programme Summary Interim report (March 2009) MRSA screening in acute inpatient settings commenced in the Pathfinder NHS Boards in August A total of 29, 690 patients were screened for MRSA. Findings 3.8% of admissions to hospitals in Pathfinder NHS Boards, laboratory confirmed, colonised with MRSA. 1 in 5 admissions to hospital in the four specialities were found to be colonised with MRSA. These were nephrology, care of the elderly, dermatology and vascular surgery. On 8th April 2009 the Cabinet Secretary for Health and Wellbeing announced a national MRSA screening programme should be rolled out across NHSScotland. 12

13 MRSA Screening National Implementation Programme. Who is to be screened for MRSA? All patients undergoing elective admission to acute hospitals (excluding paediatrics, obstetrics and psychiatric admissions). All elective and emergency patient admissions, including patients transferred, to the four specialities of nephrology, vascular surgery, dermatology and care of elderly. Remember this only applies to patients who stay overnight. Day cases should not be screened. This is to be implemented by all NHS Boards by 31st January Q. Where can I get more information? You can get more information on MRSA from a leaflet called MRSA Information For Patients. You can find this leaflet in the leaflet rack on the ward or department, or please ask a member of staff to give you one. If you have any more questions about the screening, please ask a member of staff. For more general information about MRSA visit This leaflet is available in other languages as well as in large print, in Braille (English only) and on audio tape. To ask for a copy of this leaflet in another language or format, please contact our communications officer at: Clifton House, Clifton Place, Glasgow G3 7LN Other language options are available from the HPS web site: mrsascreeningprogramme.aspx#leaflet MRSA screening Information for patients Note: Staff must refer to their local NHS Board MRSA screening policy as additional screening may be carried out as part of a local risk assessments for MRSA. 2009_09_22 MRSA Screening Information for Patients (V2) MRSA leaflet - nationalv2.indd 1 16/10/ :06:42 13

14 Why are healthcare staff not being screened for MRSA? A recent literature review carried out by Health Protection Scotland found no published controlled studies examining the impact of routine screening of healthcare staff as an intervention in the prevention and control of MRSA infections in the endemic setting. In addition the following factors mean staff screening for MRSA is not currently taking place; Staff can become transiently colonised testing positive at the end of a shift and negative by the time they return to work the next day. Healthcare workers are likely to have ongoing exposure to MRSA colonised patients. Therefore, staff who test negative on one occasion may subsequently test positive. Similarly, staff who have been de-colonised may be re-colonised following treatment. Therefore further research is required to determine the clinical and cost effectiveness of staff screening for MRSA as an infection control measure. 14

15 MRSA Screening in NHS Boards Staff should always check local MRSA policy on MRSA screening as there may be additional screening carried out locally out with the national rollout programme. Within every NHS Board there will be a Project Manager or Team for the MRSA screening programme who can be contacted for further advice. 15

16 Section 3. How to take a nasal swab? This section will describe the process of taking a nasal swab.

17 The equipment or facilities that are required to be in place prior to taking a nasal swab This will include a swab, a microbiology specimen request form and transport specimen bag. Ensure you have a supply of information leaflets for patients on MRSA screening. These leaflets are available in alternative languages, large print and Braille. Copies can be obtained from your local MRSA Project Team. Ensure you have access to hand hygiene facilities with liquid soap and paper towels or alcohol gel/ handrub/foam. You will require non sterile gloves. Refer to local glove policy for glove type. 17

18 Care of the patient prior to MRSA screening Ensure the patient has privacy. Introduce yourself to the patient. Explain the procedure to the patient outlining the reason for MRSA screening, the type of swab to be taken. Provide an information leaflet for the patient on MRSA screening. Allow time for the patient to ask questions. Inform patient of local procedures for contacting them if MRSA is identified from their sample. Seek the patient s verbal consent prior to taking a nasal swab. 18

19 How to take a nasal swab? If patient has nasal discharge ask them to clear the discharge by blowing his or her nose into a non scented tissue. Wash your hands with liquid soap and dry with disposable paper towels. Alternatively, if hands are visibly clean use alcohol gel/handrub/foam. Put on nonsterile gloves. Refer to local policy on glove use. Open and remove sterile tipped swab applicator from transporting casing. You will require non sterile gloves. Refer to local glove policy for glove type. 19

20 How to take a nasal swab? Direct the swab upward to the tip of the nose. Taking care to avoid skin contact with swab. Insert the swab approximately 2cm into one of the nostril. Gently rotate around the nostril area for 3-5 seconds. Repeat this process with the other nostril using the same swab. Remove from the nostril and carefully place swab back into transport casing and secure. 20

21 How to take a nasal swab? Fill in the appropriate patient detail as requested (or affix patient label) on the outer aspect of the transport tube. Ensure that date and time the swab was collected are included, as well as patient location. See the following slide for information on how to complete a specimen request form. Place swab specimen and microbiology specimen form in transport specimen bag. Leave for collection in designated area as per local procedure for uplift and transfer to the laboratory. If the collection is delayed and/or the swab is left overnight, place in dedicated specimen fridge until the next collection is due. If a dedicated specimen fridge is not available refer to local policy for the transportation of specimens. 21

22 How to complete specimen request form There maybe slight variation due to local policy but normally the following information is required: Name / Age / Date of Birth CHI number (if available) Location (either ward area/pre-assessment clinic) Test request: culture and sensitivity Purpose/rationale: MRSA screening Date and time sample collected Antibiotic currently prescribed Specimen type (e.g. nasal swab) Reason for admission Note: the above is the minimum dataset and is mandatory. Specimens may not be processed if this is not provided. Remember only one form is required even if more than one swab is taken from the same patient. Each swab should be clearly identify the sample site. 22

23 Sample Microbiology Form Surname Urinary Tract Dysuria Frequency Urgency Loin pain Abdo pain Prostatitis Respiratory Tract Bronchiectasis Sinusitis COPD Pneumonia AREA LABORATORY MICROBIOLOGY L A B E L Urogenital Urethral/Vaginal discharge STI Screen PID Vulvitis Balanitis Gastrointestinal Diarrhoea Nausea Vomiting Dyspepsia First Name Patient's Address Date of Birth Sex CHI No. Skin/Soft Tissue Bite Cellulitis Wound infection site of wound: Rash/lesion? Eczema Nervous System Fit/s Headache Meningism Bone/Joint Osteomyelitis Joint prosthesis Septic Arthritis Reactive Arthritis Consultant / GP Date of onset Date of Specimen Initials & Bleep ALL SAMPLES SHOULD BE ADEQUATELY LABELLED. INADEQUATELY LABELLED SAMPLES WILL NOT BE PROCESSED.? Gout ENT/Eyes Conjunctivitis Otitis media Otitis externa Sore Throat Time Ward / G.P. Address Specimen type, site and request(s) Relevant Clinical Details (continue overleaf if required) Other Inoculation Risk YES NO Antibiotic History: Previous/Current/Proposed... Dose & time (for Antibiotic Assays)... Fever (>37.8)/chills Routine/Asymptomatic/screening Pregnant Immunocompromised Diabetes NAME... DATE... REQUEST... 23

24 Section 4. Processing of nasal swabs in the Microbiology department. This section will describe the process of culturing the swab and antibiotic sensitivity tests within the microbiology laboratory.

25 What happens to the swab in the microbiology department? Bacteria need to grow to be identified in the laboratory. They are grown on special media that is called agar. The agar contains nutrients which encourage the growth of bacteria. MRSA specific agars contain antibiotics to minimise the growth of bacteria other than MRSA, and dyes to help distinguish MRSA growth from other bacteria. 25

26 What happens to the swab in microbiology department part 2. Each sample that arrives is given a unique identification number, and is entered into the laboratory computer system. The sample is inoculated (spread) onto the agar plate. The plate is then incubated at 37 C to encourage growth. After 24 hours the plate is removed from the incubator. The micro-organisms appear as small colonies on the plate. Coloured colonies are lifted from the plate for further work to confirm the identification of MRSA. 26

27 MRSA colonies (one of the MRSA specific agars) 27

28 Microbiology processing of a suspected MRSA Coloured colonies (blue in this example) are tested for the presence of an enzyme to confirm the micro-organism is a Staphylococcus aureus. If this test is negative, no further work is done, and a MRSA negative report issued. If the enzyme test is positive, antibiotic sensitivity testing is done to confirm whether the micro-organism is MRSA. Antibiotic testing is performed in a machine that tests the suspect microorganism against a range of antibiotics. The unique identification number of each sample means the results are electronically transferred to the laboratory computer system. 28

29 Time to Results Negative results should be available the following day, usually 24 hours after being processed. Remember this is not necessarily 24 hours after being taken. Positive results require the initial 24 hours and at least another 24 hours for antibiotic sensitivity work. Sometimes a further 24 hours depending on how much MRSA is grown. Turnaround times may vary as not all laboratories follow this precise method 29

30 Further Actions Laboratories will store all new all new samples identified as MRSA to ensure the organisms are available for further testing if required. Laboratories report all isolates to Health Protection Scotland via electronic system. 30

31 Reporting positive MRSA results Infection Control Teams should be informed of all new MRSA isolates promptly. Depending on local policy the Infection Control Teams or the Laboratory will inform Ward and Medical staff. Once confirmed, results will be available on local Laboratory/information systems. Results will be sent to the requestor either electronically on hard copy or both depending on local policy. 31

32 Section 5. Action to be taken on receipt of a positive MRSA results This section will describe what action should be taken on receipt of a positive result including who should be contacted.

33 Treatment of patient found to have MRSA A decolonisation regime for MRSA may be carried out. You must refer to local policy as this may differ between NHS Board areas. Further advice can be obtained by contacting your local Infection Control Team. A decolonisation regime can help reduce or remove the MRSA bacteria from hair, skin and nostrils. A decolonisation regime consists of an antiseptic wash to be used on the body and hair and a nasal ointment for the nostrils. Decolonisation products must be prescribed. Follow local procedures. Antibiotic treatment (oral or intravenous medication) will only be initiated where the patient has a MRSA infection. This is confirmed by identifying MRSA from wounds or other samples in conjunction with the patient having relevant clinical symptoms. 33

34 What happens if a patient is found to have MRSA and is staying in hospital? MRSA can spread to other patients therefore Standard Infection Control Precautions (SICPS) and appropriate Transmission Based Precautions (TBP) should be applied to prevent transmission or spread of MRSA. This may mean source isolation precautions are necessary and the patient may require single room facilities. As highlighted previously you must inform the Infection Control Team that MRSA has been identified and seek advice on appropriate management of the patient. A decolonisation procedure may be required and you should refer to local policy. The medical team in charge of the patient s care must be informed that the patient has been identified with MRSA. 34

35 If a patient is identified as having MRSA following pre-admission MRSA screening. Make sure you are aware of local policy for informing patients in the community of their MRSA status and issuing decolonisation regimes. The patient may be issued a decolonisation regime and the method of issue will vary in NHS Boards. The patient will be given supporting material advising on how to carry out the decolonisation and will be given a contact name or number to call if they require further assistance. Make sure you are aware of local policies as systems in place to support the patients in the community will vary in NHS Boards. 35

36 Resources MRSA Screening Resource Pack - Feedback Questionnaire Please give us feedback on this resource pack by clicking on the link below. This will take you to an online questionnaire which will take a few minutes to fill in. Thank you very much for your help. 36

37 Appendix 1. Hand Hygiene

38 Regular and effective hand hygiene is the single-most important thing you can do to protect yourself and others from infection. Promoting Hand Hygiene in Healthcare was developed from the Cleanliness Champion programme and has been adapted to stand alone as a learning package. It is designed to be used by any healthcare worker, student or carer within hospital or community wishing to update, refresh or challenge personal hand hygiene knowledge and practice. This resource can be accessed by linking to: 38

39 Appendix 2. Questions & Answers

40 Questions 1. MRSA is a virus. 2. MRSA is resistant to ALL antibiotics. 3. People who are colonised with MRSA will show signs and symptoms of an infection. 4. The most common area of carriage of MRSA is in the nose. 5. Patient admitted routinely to paediatric, obstetric and psychiatric specialities will be screened as part of the routine screening programme. 6. It is important to seek the patients verbal consent prior to taking a nasal swab. 7. It is not necessary to carry out hand hygiene prior to taking a nasal swab. 8. MRSA can take up to forty eight hours to grow in the laboratory. 9. It is not necessary to inform the Infection control team if inpatient Is identified as carrying MRSA. 10. It is vital to be aware of local policies and procedure for the screening for MRSA and decolonisation regimes as this may vary between Health Boards. True False 40

41 Answers to Questions 1. False. MRSA is a bacterium (micro-organisms) Slide False. MRSA is resistant to an antibiotic called meticillin thus the name Meticillin-resistant Staphylococcus aureus. This means it is resistant to flucloxacillin, the antibiotic often used to treat Staphylococcus aureus infections. It may also be resistant to a variety of other antibiotics. Slide False. A patient from whom MRSA is identified but has no signs or symptoms of an infection is said to be colonised with MRSA. Slide True. The nose is the most common carriage site for MRSA. Slide False. All elective and emergency patient admissions including patients transferred to the four specialities of nephrology, vascular surgery, dermatology and care of elderly. Remember this only applies to patients who stay overnight. Day cases should not be screened. Slide True. The patient should give verbal consent prior to taking a nasal swab. Slide

42 Answers to Questions. Continued 7. False. Hands must be washed with liquid soap and dry with disposable paper towels prior to taking a nasal swab. Alternatively, if hands are visibly clean use alcohol gel/handrub/foam. Slide True. Positive results require the initial 24 hours and at least another 24 hours for antibiotic sensitivity work. Sometimes a further 24 hours depending on how much MRSA is grown. Slide False. You must inform infection control team that MRSA has been identified and seek advice on appropriate management of the patient. Slide True. It is vital to be aware of local policies and procedure for the screening for MRSA and decolonisation regimes as this may vary between Health Boards. Slide

A patient s guide to. MRSA - Methicillin Resistant Staphylococcus Aureus

A patient s guide to. MRSA - Methicillin Resistant Staphylococcus Aureus A patient s guide to MRSA - Methicillin Resistant Staphylococcus Aureus 1 What is MRSA? There are lots of micro-organisms (germs) on our skin. They are in the air we breathe, the water we drink, and the

More information

About MRSA. MRSA (sometimes referred to as a superbug) stands for meticillin resistant Staphylococcus aureus.

About MRSA. MRSA (sometimes referred to as a superbug) stands for meticillin resistant Staphylococcus aureus. About MRSA Other formats If you need this information in another format such as audio tape or computer disk, Braille, large print, high contrast, British Sign Language or translated into another language,

More information

Advice for those affected by MRSA outside of hospital If you have MRSA this booklet provides information to help manage your day-to-day life

Advice for those affected by MRSA outside of hospital If you have MRSA this booklet provides information to help manage your day-to-day life Registered Charity No 1115672 raising public awareness - campaigning for safe standards supporting sufferers and dependants Patron: Edwina Currie President: Professor Hugh Pennington Advice for those affected

More information

Advice for those affected by MRSA outside of hospital

Advice for those affected by MRSA outside of hospital Advice for those affected by MRSA outside of hospital If you have MRSA this leaflet provides information and advice for managing your day-to-day life. 2 About MRSA Understanding the difference between

More information

MRSA Screening (Elective Patients)

MRSA Screening (Elective Patients) What is MRSA? MRSA stands for Meticillin resistant Staphylococcus aureus. It is a type of Staphylococcus aureus bacteria (germ) that is very resistant to antibiotics so infections due to MRSA can be quite

More information

MRSA CROSS INFECTION RISK: IS YOUR PRACTICE CLEAN ENOUGH?

MRSA CROSS INFECTION RISK: IS YOUR PRACTICE CLEAN ENOUGH? Vet Times The website for the veterinary profession https://www.vettimes.co.uk MRSA CROSS INFECTION RISK: IS YOUR PRACTICE CLEAN ENOUGH? Author : CATHERINE F LE BARS Categories : Vets Date : February 25,

More information

Your Guide to Managing. Multi Drug-resistant Organisms (MDROs)

Your Guide to Managing. Multi Drug-resistant Organisms (MDROs) Agency for Integrated Care 5 Maxwell Road #10-00 Tower Block MND Complex Singapore 069110 Singapore Silver Line: 1800-650-6060 Email: enquiries@aic.sg Website: www.silverpages.sg Facebook: www.facebook.com/carerssg

More information

HOSPITAL-ACQUIRED INFECTION/MRSA EYERUSALEM KIFLE AND GIFT IMUETINYAN OMOBOGBE PNURSS15

HOSPITAL-ACQUIRED INFECTION/MRSA EYERUSALEM KIFLE AND GIFT IMUETINYAN OMOBOGBE PNURSS15 HOSPITAL-ACQUIRED INFECTION/MRSA EYERUSALEM KIFLE AND GIFT IMUETINYAN OMOBOGBE PNURSS15 INTRODUCTION DEFINITIONS SIGNS AND SYMPTOMS RISK FACTORS DIAGNOSIS COMPLICATIONS PREVENTIONS TREATMENT PATIENT EDUCATION

More information

Role of the nurse in diagnosing infection: The right sample, every time

Role of the nurse in diagnosing infection: The right sample, every time BROUGHT TO YOU BY Role of the nurse in diagnosing infection: The right sample, every time The module has been written by Shanika Anne-Marie Crusz and Amelia Joseph Authors affiliation: Department of Clinical

More information

Delayed Prescribing for Minor Infections Resource Pack for Prescribers

Delayed Prescribing for Minor Infections Resource Pack for Prescribers Delayed Prescribing for Minor Infections Resource Pack for Prescribers Background: Antibiotic resistance is an alarming threat to modern healthcare, and infectious illness remains a major global threat

More information

MRSA. Patient Screening Information

MRSA. Patient Screening Information MRSA Patient Screening Information WHAT IS MRSA? First identified in the 1960s, MRSA is an abbreviation of Meticillin Resistant Staphylococcus Aureus. MRSA is a bacteria that has developed resistance to

More information

South Staffordshire and Shropshire Healthcare NHS Foundation Trust

South Staffordshire and Shropshire Healthcare NHS Foundation Trust South Staffordshire and Shropshire Healthcare NHS Foundation Trust Document Version Control Document Type and Title: Authorised Document Folder: New or Replacing: Document Reference: Version No. v1.0 Policy

More information

Today s Agenda: 9/30/14

Today s Agenda: 9/30/14 Today s Agenda: 9/30/14 1. Students will take C List Medical Abbreviation Quiz. 2. TO: Discuss MRSA. MRSA MRSA Methicillin Resistant Staphylococcus Aureus Methicillin Resistant Staphylococcus Aureus What

More information

Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version

Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED 2018 Printed copies must not be considered the definitive version DOCUMENT CONTROL POLICY NO. IC-122 Policy Group Infection Control

More information

Multi-Drug Resistant Organisms (MDRO)

Multi-Drug Resistant Organisms (MDRO) Multi-Drug Resistant Organisms (MDRO) 2016 What are MDROs? Multi-drug resistant organisms, or MDROs, are bacteria resistant to current antibiotic therapy and therefore difficult to treat. MDROs can cause

More information

Scottish Surveillance of Healthcare Infection Programme (SSHAIP) Health Protection Scotland SSI Surveillance Protocol 7th Edition 2017 Question &

Scottish Surveillance of Healthcare Infection Programme (SSHAIP) Health Protection Scotland SSI Surveillance Protocol 7th Edition 2017 Question & Contents General... 4 Pre-op... 4 Peri-op... 5 Post-op... 8 Caesarean Section... 12 Orthopaedics... 14 Large Bowel:... 15 Vascular... 17 General Pre-op Q: If a patient is an emergency admission is the

More information

Living with MRSA Learning how to control the spread of Methicillin-Resistant Staphylococcus Aureus (MRSA)

Living with MRSA Learning how to control the spread of Methicillin-Resistant Staphylococcus Aureus (MRSA) Living with MRSA Learning how to control the spread of Methicillin-Resistant Staphylococcus Aureus (MRSA) IMPORTANT MRSA is a serious infection that can become life-threatening if left untreated. If you

More information

NHS GRAMPIAN MRSA POLICY FOR COMMUNITY SETTINGS JUNE 2003

NHS GRAMPIAN MRSA POLICY FOR COMMUNITY SETTINGS JUNE 2003 NHS GRAMPIAN MRSA POLICY FOR COMMUNITY SETTINGS JUNE 2003 Grampian NHS Board Grampian University Hospitals Trust Grampian Primary Care Trust TABLE OF CONTENTS Aim 3 1 Introduction 4 2 Control of MRSA in

More information

MRSA in the United Kingdom status quo and future developments

MRSA in the United Kingdom status quo and future developments MRSA in the United Kingdom status quo and future developments Dietrich Mack Chair of Medical Microbiology and Infectious Diseases The School of Medicine - University of Wales Swansea P R I F Y S G O L

More information

Treatment of Surgical Site Infection Meeting Quality Statement 6. Prof Peter Wilson University College London Hospitals

Treatment of Surgical Site Infection Meeting Quality Statement 6. Prof Peter Wilson University College London Hospitals Treatment of Surgical Site Infection Meeting Quality Statement 6 Prof Peter Wilson University College London Hospitals TEG Quality Standard 6 Treatment and effective antibiotic prescribing: People with

More information

Hand washing/hand hygiene reduces the number of microorganisms on the hands and is the most important practice to prevent the spread of infection.

Hand washing/hand hygiene reduces the number of microorganisms on the hands and is the most important practice to prevent the spread of infection. 1. Hand Hygiene Quick Reference Chart Hand washing/hand hygiene reduces the number of microorganisms on the hands and is the most important practice to prevent the spread of infection. WHEN Before: Direct

More information

COALINGA STATE HOSPITAL. NURSING POLICY AND PROCEDURE MANUAL SECTION Emergency Procedures POLICY NUMBER: 705. Effective Date: August 31, 2006

COALINGA STATE HOSPITAL. NURSING POLICY AND PROCEDURE MANUAL SECTION Emergency Procedures POLICY NUMBER: 705. Effective Date: August 31, 2006 COALINGA STATE HOSPITAL NURSING POLICY AND PROCEDURE MANUAL SECTION Emergency Procedures POLICY NUMBER: 705 Effective Date: August 31, 2006 SUBJECT: EMERGENCY CARE OF WOUNDS (FIRST AID) 1. PURPOSE: Proper

More information

To guide safe and appropriate selection of antibiotic therapy for Peritoneal Dialysis patients.

To guide safe and appropriate selection of antibiotic therapy for Peritoneal Dialysis patients. Nephrology Directorate Subject: Objective: Prepared by: Aintree Antibiotic Guidelines for Peritoneal Dialysis (PD): Catheter Insertion, and the Diagnosis and Treatment of PD Peritonitis and Exit-Site Infections.

More information

Screening for MRSA / MSSA and CPO within the Kent Kidney Care Centre

Screening for MRSA / MSSA and CPO within the Kent Kidney Care Centre Screening for MRSA / MSSA and CPO within the Kent Kidney Care Centre Information for patients from the Infection Prevention and Control Team and the Renal Team This leaflet is not meant to replace the

More information

Overview of Infection Control and Prevention

Overview of Infection Control and Prevention Overview of Infection Control and Prevention Review of the Cesarean-section Antibiotic Prophylaxis Program in Jordan and Workshop on Rational Medicine Use and Infection Control Terry Green and Salah Gammouh

More information

Approval Signature: Original signed by Dr. Michel Tetreault Date of Approval: July Review Date: July 2017

Approval Signature: Original signed by Dr. Michel Tetreault Date of Approval: July Review Date: July 2017 WRHA Infection Prevention and Control Program Operational Directives Admission Screening for Antibiotic Resistant Organisms (AROs): Methicillin Resistant Staphylococcus aureus (MRSA) and Vancomycin Resistant

More information

Volume 2; Number 16 October 2008

Volume 2; Number 16 October 2008 Volume 2; Number 16 October 2008 What s new this month NHS Lincolnshire have launched a public information campaign designed to raise public awareness of the risks associated with the inappropriate use

More information

MRSA Information for patients, staff and relatives

MRSA Information for patients, staff and relatives MRSA Information for patients, staff and relatives MRSA info nov 17.indd 1 17/11/2017 16:18 What is MRSA? MRSA stands for meticillin (M) resistant (R) Staphylococcus (S) aureus (A). It is a variety of

More information

Staph and MRSA Skin Infections Fact Sheet for Schools

Staph and MRSA Skin Infections Fact Sheet for Schools Cape May County Department of Health 4 Moore Road, Cape May Court House, NJ 08210 Staph and MRSA Skin Infections Fact Sheet for Schools What is a staph/mrsa skin infection? Staphylococcus or staph bacteria

More information

NHS Scotland MRSA Screening Pathfinder Programme

NHS Scotland MRSA Screening Pathfinder Programme NHS Scotland MRSA Screening Pathfinder Programme Update Report Prepared for the Scottish Government HAI Task Force by Health Protection Scotland Delivered October 2010 Published February 2011 Ayrshire

More information

Management of Meticillin resistant Staphylococcus

Management of Meticillin resistant Staphylococcus SBC Children, Families and Community Health Service Management of Meticillin resistant Staphylococcus aureus (MRSA) Statement of Intent To provide healthcare staff with clear guidelines for the effective

More information

appropriate healthcare professionals employed at my pharmacy. I understand that I am

appropriate healthcare professionals employed at my pharmacy. I understand that I am Patient Group Direction: For the supply of Silver Sulfadiazine 1% Cream by Community Pharmacists in Somerset to patients for the topical treatment of minor localised impetigo under the Somerset Minor Ailments

More information

Please call the Pharmacy Medicines Unit on or for a copy.

Please call the Pharmacy Medicines Unit on or for a copy. Title: PATIENT GROUP DIRECTION FOR THE SUPPLY OF CHLORAMPHENICOL EYE DROPS 0.5% UNDER THE MINOR AILMENT SERVICE Identifier: Across NHS Boards Organisation Wide Directorate Clinical Service Sub Department

More information

Running head: CLOSTRIDIUM DIFFICILE 1

Running head: CLOSTRIDIUM DIFFICILE 1 Running head: CLOSTRIDIUM DIFFICILE 1 Clostridium difficile Infection Christy Lee Fenton Mountainland Applied Technology College CLOSTRIDIUM DIFFICILE 2 Clostridium difficile Infection Approximately 200,000

More information

Medical Director Board Paper No. 10/43. Healthcare Associated Infection Reporting Template (HAIRT)

Medical Director Board Paper No. 10/43. Healthcare Associated Infection Reporting Template (HAIRT) NHS Board Meeting th October Medical Director Board Paper No. /3 Recommendation: Healthcare Associated Infection Reporting Template (HAIRT) The NHS Board is asked to note the latest monthly report on HAI

More information

Breastfeeding Challenges - Mastitis & Breast Abscess -

Breastfeeding Challenges - Mastitis & Breast Abscess - CLINICAL PRACTICE GUIDELINE Breastfeeding Challenges - Mastitis & Breast Abscess - SCOPE (Area): Maternity Unit, Emergency Department, Paediatrics SCOPE (Staff): Medical, Midwifery & Nursing DESIRED OUTCOME/OBJECTIVE

More information

Antibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents

Antibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents Antibiotic Prophylaxis in Spinal Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Authors Division: DCSS & Tertiary Medicine Unique

More information

INFECTIONS IN CHILDREN-ANTIMICROBIAL MANAGEMENT

INFECTIONS IN CHILDREN-ANTIMICROBIAL MANAGEMENT INFECTIONS IN CHILDREN-ANTIMICROBIAL MANAGEMENT Name & Title Of Authors: Dr M Milupi, Consultant Microbiologist Dr N Rao,Consultant Paediatrician Dr V Desai Consultant Paediatrician Date Revised: DEC 2015

More information

Protocol for exit-site care and treatment of exit-site infections in peritoneal dialysis CONTROLLED DOCUMENT

Protocol for exit-site care and treatment of exit-site infections in peritoneal dialysis CONTROLLED DOCUMENT CONTROLLED DOCUMENT Protocol for exit-site care and treatment of exit-site infections in peritoneal dialysis CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Guideline Clinical The purpose

More information

M R S A. Methicillin-Resistant Staphylococcus aureus. The Facts

M R S A. Methicillin-Resistant Staphylococcus aureus. The Facts M R S A Methicillin-Resistant Staphylococcus aureus The Facts Michael Parry, M.D. Director of Infectious Diseases and Microbiology Stamford Hospital January 24, 2008 Introduction to Staph aureus Staphylococcus

More information

Carbapenemase-Producing Enterobacteriaceae (CPE)

Carbapenemase-Producing Enterobacteriaceae (CPE) Carbapenemase-Producing Enterobacteriaceae (CPE) September 21, 2017 Maryam Khan Peel Public Health Madeleine Ashcroft Public Health Ontario Objectives Differentiate the acronyms related to CPE (CPE,CPO,CRE,CRO)

More information

So Why All the Fuss About Hand Hygiene?

So Why All the Fuss About Hand Hygiene? CARING PROFESSIONAL SERVICES, INC. HAND HYGIENE In-Service So Why All the Fuss About Hand Hygiene? Most common mode of transmission of pathogens is via hands! Infections acquired in healthcare Spread of

More information

Infection Control and Standard Precautions

Infection Control and Standard Precautions Home Care Aide Training Guide Infection Control and Standard Precautions Pre-Service Training Course #1 Home Care Aide Orientation Training Manual: Infection Control & Standard Precautions Page 2 Table

More information

Health Service Executive Parkgate St. Business Centre, Dublin 8 Tel:

Health Service Executive Parkgate St. Business Centre, Dublin 8 Tel: Health Service Executive Parkgate St. Business Centre, Dublin 8 Tel: 01 635 2500 www.hse.ie Health Service Executive Oak House, Millennium Park, Naas, Co. Kildare Tel: 045 880 400 www.hse.ie The prevention

More information

Volume. December Infection. Notes. length of. cases as 90% 1 week. tonsillitis. First Line. sore throat / daily for 5 days. quinsy >4000.

Volume. December Infection. Notes. length of. cases as 90% 1 week. tonsillitis. First Line. sore throat / daily for 5 days. quinsy >4000. Volume 8; Number 22 LINCOLNSHIRE GUIDELINES FOR THE TREATMENT OF COMMONLYY OCCURRING INFECTIONS IN PRIMARY CARE: WINTER 2014/15 In this issue of the PACE Bulletin we present an update of our Guidelines

More information

Healthcare-associated infections surveillance report

Healthcare-associated infections surveillance report Healthcare-associated infections surveillance report Methicillin-resistant Staphylococcus aureus (MRSA) Update, Q3 of 2017/18 Summary Table Q3 2017/18 Previous quarter (Q2 2017/18) Same quarter of previous

More information

Symptoms of cellulitis (n=396) %

Symptoms of cellulitis (n=396) % Cellulitis and lymphoedema Vaughan Keeley May 2012 What is cellulitis? - also called erysipelas, acute inflammatory episodes etc. - bacterial infection of skin + subcutaneous tissues - more common in people

More information

Conflict of interest: We have no conflict of interest to report on this topic of SSI reduction for total knees.

Conflict of interest: We have no conflict of interest to report on this topic of SSI reduction for total knees. Reducing SSI- Knees TIFFANY KENNERK MBA, MSN, RN, NE -BC, ONC CYNTHIA SEAMAN BSN, RN, ONC, CMSRN ~COMMUNITY HOSPITALS AND WELLNESS CENTERS~ Conflict of interest: We have no conflict of interest to report

More information

Surveillance of Multi-Drug Resistant Organisms

Surveillance of Multi-Drug Resistant Organisms Surveillance of Multi-Drug Resistant Organisms Karen Hoffmann, RN, MS, CIC Associate Director Statewide Program for Infection Control and Epidemiology (SPICE) University of North Carolina School of Medicine

More information

Do Bugs Need Drugs? A community program for wise use of antibiotics

Do Bugs Need Drugs? A community program for wise use of antibiotics Do Bugs Need Drugs? A community program for wise use of antibiotics June 2012 Antibiotics Most significant discovery of modern medicine Save millions of lives Antibiotic resistance Caused by overuse and

More information

Carbapenemase-producing Enterobacteriaceae (CRE) T H E L A T E S T I N T H E G R O W I N G L I S T O F S U P E R B U G S

Carbapenemase-producing Enterobacteriaceae (CRE) T H E L A T E S T I N T H E G R O W I N G L I S T O F S U P E R B U G S Carbapenemase-producing Enterobacteriaceae (CRE) T H E L A T E S T I N T H E G R O W I N G L I S T O F S U P E R B U G S CRE Enterobacteriaceae (Gram Negative Bacilli) Citrobacter species Escherichia coli***

More information

The trinity of infection management: United Kingdom coalition statement

The trinity of infection management: United Kingdom coalition statement * The trinity of infection management: United Kingdom coalition statement This coalition statement, on behalf of our organizations (the UK Sepsis Trust, Royal College of Nursing, Infection Prevention Society,

More information

Antibiotic Guideline: Empirical Treatment of Bone and Joint Infection in Adults

Antibiotic Guideline: Empirical Treatment of Bone and Joint Infection in Adults Antibiotic Guideline: Empirical Treatment of Bone and Joint Infection in Adults Document type: Prescribing guideline Version: 5.0 Author (name and designation) Samim Patel, Antimicrobial Lead Pharmacist

More information

TABLE OF CONTENTS. 1. Purpose of the WRHA Infection Prevention and Control Manual 2.1 and approval process

TABLE OF CONTENTS. 1. Purpose of the WRHA Infection Prevention and Control Manual 2.1 and approval process TABLE OF CONTENTS Winnipeg Regional Health Authority Introduction Page Number 1. Purpose of the WRHA Infection Prevention and Control Manual 2.1 and approval process 2. WRHA Infection Prevention and Control

More information

New Zealand Consumer Medicine Information

New Zealand Consumer Medicine Information New Zealand Consumer Medicine Information FLUCLOXACILLIN Flucloxacillin (as the sodium salt) 250 mg and 500 mg capsules Flucloxacillin (as the sodium salt) 125 mg/5 ml and 250 mg/5 ml powder for oral solution

More information

03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline

03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline Infection Prevention and Control A Foundation Course 2014 What is healthcare-associated infection (HCAI), antimicrobial resistance (AMR) and multi-drug resistant organisms (MDROs)? Why we should be worried?

More information

2.0 Scope These guidelines refer to all Cheshire Ireland employees, service users, their relatives, carers and visitors.

2.0 Scope These guidelines refer to all Cheshire Ireland employees, service users, their relatives, carers and visitors. Status: Guideline: Offers direction and guidance on good practice, need not necessarily be strictly adhered to. Title: Guidelines for Hand Hygiene Written by: Clinical Practice Project Group Policy No:

More information

Update on Fluoroquinolones. Charles Krasner, M.D. June 16, 2016 Antibiotic Stewardship Program -ECHO

Update on Fluoroquinolones. Charles Krasner, M.D. June 16, 2016 Antibiotic Stewardship Program -ECHO Update on Fluoroquinolones Charles Krasner, M.D. June 16, 2016 Antibiotic Stewardship Program -ECHO Potential fluoroquinolone side-effects Increased risk, greater than with most other antibiotics, for

More information

PVL Staph aureusjust a skin/soft tissue problem? Layla Mohammadi Lead Pharmacist, Antimicrobials Lewisham Healthcare NHS Trust

PVL Staph aureusjust a skin/soft tissue problem? Layla Mohammadi Lead Pharmacist, Antimicrobials Lewisham Healthcare NHS Trust PVL Staph aureusjust a skin/soft tissue problem? Layla Mohammadi Lead Pharmacist, Antimicrobials Lewisham Healthcare NHS Trust Neonatal Case History Neonate born at 26 +2 gestation Spontaneous onset of

More information

Package leaflet: Information for the patient. FLUCLOXACILLIN 250MG/5ML ORAL SOLUTION Flucloxacillin

Package leaflet: Information for the patient. FLUCLOXACILLIN 250MG/5ML ORAL SOLUTION Flucloxacillin Package leaflet: Information for the patient FLUCLOXACILLIN 250MG/5ML ORAL SOLUTION Flucloxacillin Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

Antimicrobial Update Stewardship in Primary Care. Clare Colligan Antimicrobial Pharmacist NHS Forth Valley

Antimicrobial Update Stewardship in Primary Care. Clare Colligan Antimicrobial Pharmacist NHS Forth Valley Antimicrobial Update Stewardship in Primary Care Clare Colligan Antimicrobial Pharmacist NHS Forth Valley Setting the Scene! Consequences of Antibiotic Use? Resistance For an individual patient with

More information

Carbapenemase-Producing Enterobacteriaceae Multi Drug Resistant Organism Management Procedure. (IPC Manual)

Carbapenemase-Producing Enterobacteriaceae Multi Drug Resistant Organism Management Procedure. (IPC Manual) Carbapenemase-Producing Enterobacteriaceae Multi Drug Resistant Organism Management Procedure (IPC Manual) DOCUMENT CONTROL: Version: 1 Ratified by: Clinical Policies Review and Approval Group Date ratified:

More information

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018 Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?

More information

Author of PGD: Adrian MacKenzie, Lead Pharmacist, Community Pharmacy.

Author of PGD: Adrian MacKenzie, Lead Pharmacist, Community Pharmacy. Patient Group Direction for the supply of Chloramphenicol 0.5% eye drops to named patients registered with the Minor Ailment Service attending Community Pharmacies in NHS Borders This document authorises

More information

Nosocomial Antibiotic Resistant Organisms

Nosocomial Antibiotic Resistant Organisms Nosocomial Antibiotic Resistant Organisms Course Medical Microbiology Unit II Laboratory Safety and Infection Control Essential Question Does improved hand hygiene really reduce the spread of bacteria

More information

Gynaecological Surgery in Adults Surgical Antibiotic Prophylaxis

Gynaecological Surgery in Adults Surgical Antibiotic Prophylaxis Gynaecological Surgery in Adults Surgical Antibiotic Prophylaxis Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date

More information

Infection control in intensive care. Sandra Fairley Senior Nurse, Neurocritical Care

Infection control in intensive care. Sandra Fairley Senior Nurse, Neurocritical Care Infection control in intensive care Sandra Fairley Senior Nurse, Neurocritical Care sandra.fairley@uclh.nhs.uk Risks to the patient of health care acquired infection (HCAI) Patient admitted to hospital

More information

Healthcare-associated infections surveillance report

Healthcare-associated infections surveillance report Healthcare-associated infections surveillance report Methicillin-resistant Staphylococcus aureus (MRSA) Update, Q4 2015/16 Summary Table Q4 2015/2016 Previous quarter (Q3 2015/16) Same quarter of previous

More information

Prevalence & Risk Factors For MRSA. For Vets

Prevalence & Risk Factors For MRSA. For Vets For Vets General Information Staphylococcus aureus is a Gram-positive, aerobic commensal bacterium of humans that is carried in the anterior nares of approximately 30% of the general population. It is

More information

SURGICAL ANTIBIOTIC PROPHYLAXIS GUIDELINES WITHIN ORTHOPAEDIC SURGERY FOR ADULT PATIENTS

SURGICAL ANTIBIOTIC PROPHYLAXIS GUIDELINES WITHIN ORTHOPAEDIC SURGERY FOR ADULT PATIENTS SURGICAL ANTIBIOTIC PROPHYLAXIS GUIDELINES WITHIN ORTHOPAEDIC SURGERY FOR ADULT PATIENTS Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if

More information

Neurosurgery Antibiotic Prophylaxis Guideline

Neurosurgery Antibiotic Prophylaxis Guideline Neurosurgery Antibiotic Prophylaxis Guideline Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date (when this version

More information

Volume 1; Number 7 November 2007

Volume 1; Number 7 November 2007 Volume 1; Number 7 November 2007 CONTENTS Page 1 Page 3 Guidance on the Use of Antibacterial Drugs in Lincolnshire Primary Care: Winter 2007/8 NICE Clinical Guideline 54: Urinary Tract Infection in Children

More information

Healthcare-associated Infections Annual Report December 2018

Healthcare-associated Infections Annual Report December 2018 December 2018 Healthcare-associated Infections Annual Report 2011-2017 TABLE OF CONTENTS INTRODUCTION... 1 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS... 2 MRSA SURVEILLANCE... 3 CLOSTRIDIUM

More information

Infection Prevention Highlights for the Medical Staff. Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention

Infection Prevention Highlights for the Medical Staff. Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention Highlights for the Medical Staff Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention Standard Precautions every patient every time a. Hand Hygiene b. Use of Personal Protective Equipment (PPE)

More information

What is Antibiotic Resistance. Antibiotic Resistance A Public Health Issue

What is Antibiotic Resistance. Antibiotic Resistance A Public Health Issue What is Antibiotic Resistance Antibiotic Resistance A Public Health Issue Antibiotic resistance is the ability of a bacteria, to stop an antibiotics from working against it. As a result, standard treatments

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. AMOXICILLIN 250mg and 500mg CAPSULES BP Amoxicillin (as amoxicillin trihydrate)

PACKAGE LEAFLET: INFORMATION FOR THE USER. AMOXICILLIN 250mg and 500mg CAPSULES BP Amoxicillin (as amoxicillin trihydrate) PACKAGE LEAFLET: INFORMATION FOR THE USER AMOXICILLIN 250mg and 500mg CAPSULES BP Amoxicillin (as amoxicillin trihydrate) Read all of this leaflet carefully before you start taking this medicine because

More information

Amoxicillin 250mg Hard Capsules Amoxicillin 500mg Hard Capsules

Amoxicillin 250mg Hard Capsules Amoxicillin 500mg Hard Capsules Package leaflet: Information for the user Amoxicillin 250mg Hard Capsules Amoxicillin 500mg Hard Capsules Amoxicillin Read all of this leaflet carefully before you start taking this medicine because it

More information

Replaces:04/14/16. Formulated: 1997 SKIN AND SOFT TISSUE INFECTION

Replaces:04/14/16. Formulated: 1997 SKIN AND SOFT TISSUE INFECTION Effective Date: 04/13/17 Replaces:04/14/16 Page 1 of 7 POLICY To standardize the clinical management and housing of offenders with skin and soft tissue infections, thereby reducing the transmission and

More information

2010 ARO/CDI Prevalence Survey. MRSA [ ] VRE [ ] Clostridium difficile [ ]

2010 ARO/CDI Prevalence Survey. MRSA [ ] VRE [ ] Clostridium difficile [ ] 2010 ARO/CDI Prevalence Survey 1) Patient identifier: 2) Hospital number: 3) Is the patient currently (day of survey) infected or colonized with (check all that apply): MRSA [ ] VRE [ ] Clostridium difficile

More information

EXPERIMENT. Antibiotic Sensitivity-Kirby Bauer Diffusion Test

EXPERIMENT. Antibiotic Sensitivity-Kirby Bauer Diffusion Test EXPERIMENT Antibiotic Sensitivity-Kirby Bauer Diffusion Test Author Name Version 42-0238-00-02 Review the safety materials and wear goggles when working with chemicals. Read the entire exercise before

More information

Promoting Appropriate Antimicrobial Prescribing in Secondary Care

Promoting Appropriate Antimicrobial Prescribing in Secondary Care Promoting Appropriate Antimicrobial Prescribing in Secondary Care Stuart Brown Healthcare Acquired Infection and Antimicrobial Resistance Project Lead NHS England March 2015 Introduction Background ESPAUR

More information

FM - Male, 38YO. MRSA nasal swab (+) Due to positive MRSA nasal swab test, patient will be continued on Vancomycin 1500mg IV q12 for MRSA treatment...

FM - Male, 38YO. MRSA nasal swab (+) Due to positive MRSA nasal swab test, patient will be continued on Vancomycin 1500mg IV q12 for MRSA treatment... Jillian O Keefe Doctor of Pharmacy Candidate 2016 September 15, 2015 FM - Male, 38YO HPI: Previously healthy male presents to ED febrile (102F) and in moderate distress ~2 weeks after getting a tattoo

More information

GP Small Group education April/May 2015 Antibiotics Resistance is futile

GP Small Group education April/May 2015 Antibiotics Resistance is futile GP Small Group education April/May 2015 Antibiotics Resistance is futile Acknowledgements This material was prepared by the Clinical Quality and Education team with help gratefully received from: Topic

More information

Antibiotic prophylaxis guideline for colorectal, hepatobiliary and vascular surgery for adult patients.

Antibiotic prophylaxis guideline for colorectal, hepatobiliary and vascular surgery for adult patients. Antibiotic prophylaxis guideline for colorectal, hepatobiliary and vascular surgery for adult patients. Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience,

More information

Hantavirus: An Emerging or Endemic Infection?

Hantavirus: An Emerging or Endemic Infection? Hantavirus: An Emerging or Endemic Infection? Presented by Jason Austin Senior Environmental Health Officer Slide 1 What is Hantavirus? A group of viruses that are normally carried by rodents, such as

More information

SECOND REPORT FROM THE COMMISSION TO THE COUNCIL

SECOND REPORT FROM THE COMMISSION TO THE COUNCIL SECOND REPORT FROM THE COMMISSION TO THE COUNCIL ON THE BASIS OF MEMBER STATES REPORTS ON THE IMPLEMENTATION OF THE COUNCIL RECOMMENDATION (2002/77/EC) ON THE PRUDENT USE OF ANTIMICROBIAL AGENTS IN HUMAN

More information

Nosocomial Antibiotic Resistant Organisms MRSA & VRE

Nosocomial Antibiotic Resistant Organisms MRSA & VRE Nosocomial Antibiotic Resistant Organisms MRSA & VRE Course Health Science Unit VII Infection Control Essential Question Does improved hand hygiene really reduce the spread of bacteria in healthcare settings?

More information

Invasive Group A Streptococcus (GAS)

Invasive Group A Streptococcus (GAS) Invasive Group A Streptococcus (GAS) Cause caused by a bacterium commonly found on the skin and in the throat transmitted by direct, indirect or droplet contact with secretions from the nose, and throat

More information

Controlling MRSA in the healthcare setting An achievable goal?

Controlling MRSA in the healthcare setting An achievable goal? Controlling MRSA in the healthcare setting An achievable goal? Overview of presentation Why do we need to control MRSA? Approaches to controlling MRSA Prevention of transmission of MRSA Prevention of MRSA

More information

THIS PATIENT GROUP DIRECTION HAS BEEN APPROVED on behalf of NHS Fife by:

THIS PATIENT GROUP DIRECTION HAS BEEN APPROVED on behalf of NHS Fife by: Patient Group Direction for Named Community Pharmacists to Supply CHLORAMPHENICOL EYE DROPS 0.5% To patients aged 1 year and older Under the Minor Ailments Service. Number 114 Issued October 2016 Issue

More information

Quality indicators and outcomes in the devolved nations Scotland

Quality indicators and outcomes in the devolved nations Scotland Quality indicators and outcomes in the devolved nations Scotland Dr Jacqueline Sneddon, MRPharmS Project Lead, Scottish Antimicrobial Prescribing Group Federation of Infection Societies Conference Birmingham,

More information

Discussion Paper: Antimicrobial Resistance Sept 2014

Discussion Paper: Antimicrobial Resistance Sept 2014 Homeless Health Network Better healthcare for people who are homeless Discussion Paper: Antimicrobial Resistance Sept 2014 The Queen s Nursing Institute s Homeless Health Network shared their views on

More information

ANTIMICROBIALS PRESCRIBING STRATEGY

ANTIMICROBIALS PRESCRIBING STRATEGY Directorate of Operations Clinical Support Services Diagnostic Services Pharmacy ANTIMICROBIALS PRESCRIBING STRATEGY Reference: DCM021 Version: 2.0 This version issued: 25/04/16 Result of last review:

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. GENTAMICIN VISION 3 mg/g eye ointment Gentamicin

PACKAGE LEAFLET: INFORMATION FOR THE USER. GENTAMICIN VISION 3 mg/g eye ointment Gentamicin PACKAGE LEAFLET: INFORMATION FOR THE USER GENTAMICIN VISION 3 mg/g eye ointment Gentamicin Read all of this leaflet carefully before you start using this medicine. - Keep this leaflet. You may need to

More information

DO NOT WRITE ON or THROW AWAY THIS PAPER!

DO NOT WRITE ON or THROW AWAY THIS PAPER! What Kills Bacteria? Lab Procedure Go to the following link: http://www.glencoe.com/sites/common_assets/science/virtual_labs/ls08/ls08.html or DO NOT WRITE ON or THROW AWAY THIS PAPER! Visit my eboard

More information

National Point Prevalence Survey of Healthcare Associated Infection, Device Usage and Antimicrobial Prescribing Wales. HCAI and AMR Programme

National Point Prevalence Survey of Healthcare Associated Infection, Device Usage and Antimicrobial Prescribing Wales. HCAI and AMR Programme National Point Prevalence Survey of Healthcare Associated Infection, Device Usage and Antimicrobial Prescribing 2017 Wales HCAI and AMR Programme The Healthcare Associated Infection and Antimicrobial Resistance

More information

3.0 Treatment of Infection

3.0 Treatment of Infection 3.0 Treatment of Infection Antibiotics and Medicine National Curriculum Link Key Stage 3 Sc1:1a - 1c. 2a 2p Sc2: 2n Unit of Study Unit 8: Microbes and Disease Unit 9B: Fit and Healthy Unit 20: 20 th Century

More information

Mastitis and On-Farm Milk Cultures - A Field Study - Part 1

Mastitis and On-Farm Milk Cultures - A Field Study - Part 1 Mastitis and On-Farm Milk Cultures - A Field Study - Part 1 This two-part article discusses the results of a research project undertaken by Dr. Tim Olchowy, Senior Lecturer in Livestock Medicine, School

More information

Responders as percent of overall members in each category: Practice: Adult 490 (49% of 1009 members) 57 (54% of 106 members)

Responders as percent of overall members in each category: Practice: Adult 490 (49% of 1009 members) 57 (54% of 106 members) Infectious Diseases Society of America Emerging Infections Network 6/2/10 Report for Query: Perioperative Staphylococcus aureus Screening and Decolonization Overall response rate: 674/1339 (50.3%) physicians

More information

Unshakeable confidence

Unshakeable confidence NEW PRODUCT OF THE YEAR as voted by vets for the 2nd year running** Unshakeable confidence Osurnia is the only otitis externa* treatment that applies like a liquid and stays like a gel. Right where you

More information